Early Detection of Prostate Cancer by Liquid Biopsy


Condition: Prostate Cancer

Study Type: Interventional

Clinical Trials Identifier NCT 8-digits: NCT04556916

Sponsor: University Hospital, Montpellier

Eligibility:

  • Age: minimum 40 Years maximum N/A
  • Gender: Male

Inclusion Criteria:

  • Patient :
  • Men over 40 being suspicious of prostate cancer
  • Subject with PSA ≥ 4 and designated for biopsy
  • Subjects must be able to attend all scheduled visits and to comply with all trial procedures
  • mpMRI done before prostate biopsy
  • Subject must be covered by public health insurance
  • Signed informed consent form Inclusion Criteria Subject Control Patient patient free from prostatic disease :
  • Men over 40 with no suspicion of prostate cancer
  • Subject with PSA < 2.5 and normal digital rectal examination
  • Subject must be covered by public health insurance
  • Signed informed consent form Exclusion Criteria Patient :
  • Subject with histologically confirmed prostate cancer
  • Subject with a verified viral infection (HIV or Hepatitis)
  • Subject under Finasteride treatment
  • Subject under hormonal treatment (analogs, antagonists, androgenics)
  • Subject with other cancer diagnosed
  • Subject unable to sign consent
  • Planned longer stay outside the region that prevents compliance with the visit plan
  • Subject deprived of liberty, protected adults or vulnerable persons
  • Urinary infection ≤ 2 months
  • Subject excluding health insurance registration
  • Subject refusing to perform prostate biopsy
  • Subject who are in a dependency or employment with the sponsor or the investigator

Exclusion Criteria:

  • Patient :
  • Subject with histologically confirmed prostate cancer
  • Subject with a verified viral infection (HIV or Hepatitis)
  • Subject under Finasteride treatment
  • Subject under hormonal treatment (analogs, antagonists, androgenics)
  • Subject with other cancer diagnosed
  • Subject unable to sign consent
  • Planned longer stay outside the region that prevents compliance with the visit plan
  • Subject deprived of liberty, protected adults or vulnerable persons
  • Urinary infection ≤ 2 months
  • Subject excluding health insurance registration
  • Subject refusing to perform prostate biopsy
  • Subject who are in a dependency or employment with the sponsor or the investigator Exclusion Criteria Subject Control :
  • Subject with histologically confirmed prostate cancer
  • Subject with a verified viral infection (HIV or Hepatitis)
  • Subject under Finasteride treatment
  • Subject with other cancer diagnosed
  • Subject unable to sign consent
  • Planned longer stay outside the region that prevents compliance with the visit plan
  • Subject deprived of liberty, protected adults or vulnerable persons
  • Urinary infection ≤ 2 months
  • Subject excluding health insurance registration

View trial on ClinicalTrials.gov


email news signup